Drug
Granisetron transdermal patch
Granisetron transdermal patch is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Completion Rate
0%(0/1)
Active Trials
1(33%)
Terminated
1(33%)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_3
1
33%
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Terminated(1)
Other(1)
Detailed Status
Recruiting1
unknown1
Terminated1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
0.0%
Most Advanced
Phase 4
Trials by Phase
Phase 31 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)
Trials by Status
recruiting133%
unknown133%
terminated133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_4
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
NCT04150614
unknownphase_3
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
NCT04912271
terminatednot_applicable
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
NCT01275664
Clinical Trials (3)
Showing 3 of 3 trials
NCT04150614Phase 4
BMT-08: A Comparative Effectiveness Study of Transdermal Granisetron to Ondansetron
NCT04912271Phase 3
Granisetron Transdermal Patch for Prophylaxis of Delayed CINV
NCT01275664Not Applicable
Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3